AI chipmaker Cerebras targets $115-$125 share price in US IPO, source says

Cerebras Systems is set to begin its IPO roadshow Monday, with shares expected to price between $115 and $125 as it targets a Nasdaq listing under ticker CBRS. The AI chipmaker reported revenue of $510 million for the year ended Dec. 31, up from $290.3 million, and swung to a profit of $1.38 per share from a loss of $9.90 per share a year earlier. The company is reportedly seeking a valuation of around $40 billion and could raise up to $4 billion, highlighting strong investor interest in AI hardware.

Analysis

Cerebras’ re-pricing attempt matters less as an isolated IPO and more as a read-through on the AI hardware capital stack. If the deal clears at the high end, it validates that investors are still willing to finance a second-tier accelerator franchise at a premium multiple, which can tighten public-market comps for every private ASIC/wafer-scale vendor still hunting funding. That is modestly negative for NVDA near term because it increases headline competition and gives customers more leverage in procurement talks, but it is also a reminder that the market is broadening from “one dominant GPU vendor” to a more fragmented compute ecosystem.

The bigger second-order effect is on underwriters and IPO calendar quality. A successful launch would improve sentiment for the syndicate group and could help reopen the path for other scaled AI infrastructure names that have been waiting for a receptive window. Conversely, if pricing needs to come materially below the reported range or order quality looks weak, the signal will be that investors are no longer willing to fund growth without clearer margins and customer concentration disclosures — a risk that would hit the entire late-stage AI private complex.

For NVDA, the risk is not immediate unit displacement but pricing pressure at the margin over the next 2-4 quarters as hyperscalers use alternative silicon narratives to negotiate better terms and diversify supply. The contrarian point: the real winner may be the ecosystem around issuance rather than the issuer itself — banks, exchanges, and early private holders monetizing scarcity. The market may be overestimating near-term competitive share shifts and underestimating how much of this is simply a liquidity event for a capital-intensive niche, not a fundamental overthrow of the incumbent.

Key Decisions for Investors

• Maintain a tactical underweight in NVDA for the next 1-3 months versus a basket of AI enablers; use strength around IPO enthusiasm to fade the stock if the deal prices cleanly, since the risk/reward favors modest multiple compression rather than a material earnings reset.
• Go long NDAQ into a higher-quality IPO tape, with a 1-2 month horizon; a successful AI hardware listing can improve issuance velocity and trading activity, offering asymmetric upside versus limited downside if the offering merely proceeds.
• Buy MS/C/BCS/UBS on any post-roadshow weakness as a short-duration syndicate-benefit trade; the upside is more about fee visibility and pipeline optics than deal economics, so treat it as a 2-6 week catalyst trade.
• If Cerebras prices above the midpoint, consider a small pair trade: long IPO-adjacent brokers/exchanges vs short NVDA, targeting a 3-5% relative move if investors extrapolate competition too aggressively.
• For risk-managed exposure, prefer call spreads over outright longs on the AI hardware theme; the main risk is a lukewarm book or valuation cut, which could unwind quickly within days of pricing.